Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U6 small nuclear 1297, pseudogene (RNU6-1297P) is a human genomic element classified as a pseudogene derived from a U6 small nuclear RNA (snRNA) gene.** Pseudogenes like RNU6-1297P originate from segments of DNA that resemble functional genes but are generally non-functional due to disabling mutations or lack of regulatory elements needed for expression[1][3][5][8]. This specific pseudogene is thought to have arisen by retrotransposition—copying of snRNA into DNA and insertion into the genome, often facilitated by the LINE-1 retrotransposition mechanism[2]. Unlike functional U6 snRNA genes, which are critical for pre-mRNA splicing as a component of the spliceosome, RNU6-1297P is not believed to be transcribed into functional RNA or to participate in biological processes. Pseudogenes of this type do not serve as receptors, enzymes, transporters, or other classic therapeutic targets and they lack known biological activity or disease involvement[3][5][8]. RNU6-1297P has no known pharmacological interactions, is not used as a biomarker, and has no associated safety or therapeutic concern. Its main relevance is as a genomic marker indicating past retrotransposon activity in the human genome[2]. **Key points:** - RNU6-1297P is a pseudogene, not an active gene or therapeutic target[1][3][5][8]. - It does not code for peptide, receptor, enzyme, or have a known direct biological function; thus, it is not a drug target. - It does not currently have recognized roles in disease or serve as a biomarker[3][5][8]. - Its primary scientific interest is as evidence of retrotransposition events and genome evolution, not clinical utility[2]. **Note:** Returning "is_target: false" and "is_incorrect: true"—this entry is not a valid therapeutic or biological target; it is a non-functional pseudogene[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1297, pseudogene (RNU6-1297P).